<DOC>
	<DOCNO>NCT00967070</DOCNO>
	<brief_summary>An investigation skin sensitization potential new nicotine patch . Evaluation potential new nicotine transdermal patch cause sensitization skin repeat application .</brief_summary>
	<brief_title>Skin Sensitization Potential New Nicotine Patch</brief_title>
	<detailed_description>Study skin sensitization potential new nicotine transdermal therapeutic system ( TTS ) . A double blind , randomize , repeat patch test , single center phase I study .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy male female subject 18 65 year Heavy smoker ( 10 cigarette per day ) Having febrile infectious illness least seven day prior first administration investigational product . Women practice one combination follow method birth control : hormonal contraceptive , condom , sponge , foam , jelly , diaphragm , intrauterine device woman surgically sterilize . Subjects normal skin without excessive hair growth test area . Evidence personally sign date informed consent document indicate subject inform pertinent aspect trial . Subjects willing comply schedule visit , treatment plan trial procedure . Any visible skin disorder abnormal skin pigmentation , opinion investigator , would interfere outcome trial Dermatologic disease might interfere evaluation test site reaction History chronic , dermatological , medical , physical condition would , opinion investigator , preclude topical application test product and/or influence outcome test ( particular , immunosuppressive condition ) Clinically relevant abnormal finding physical examination A baseline score skin reaction assessment `` 0 '' area patch Pregnant ( verify betahCGtest urine ) and/or nursing woman Demonstrating active physical disease , acute chronic Any suspicion , history evidence alcohol drug abuse Any history drug hypersensitivity , asthma , urticaria severe allergic diathesis well current hay fever Any current past history chronic recurrent metabolic , renal , hepatic , pulmonary , gastrointestinal , neurological , endocrinological , immunological , psychiatric cardiovascular disease , myopathy , epileptic seizure bleed tendency . Recent myocardial infarct ( within last 3 month ) , unstable deteriorate angina pectoris , coronary artery vasospasm ( Prinzmetal 's angina ) , serious cardiac arrythmias acute stroke [ add accord Amendment No . 1 ] . Use medication within 4 week prior first treatment trial , opinion investigator , may influence trial result safety subject . Use systemic topical analgesic antihistamine within 72 hour prior trial enrollment ( except paracetamol ) systemic topical corticosteroid within 3 week trial enrollment . Subjects use nicotine product cigarette within 3 month precede trial Subjects avoid , throughout duration trial , swimming , wash back sauna intense physical activity might result excessive sweat Known sensitivity adhesive tape Known sensitivity component test product History irritation topically apply product Fissure injury skin test area Participation treatment phase clinical trial within 30 day prior treatment phase trial within 10 time respective elimination halflife investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>